HCC-Mark: a simple non-invasive model based on routine parameters for predicting hepatitis C virus related hepatocellular carcinoma

References

• Affo S, Yu LX, Schwabe RF. The role of cancer-associated fibroblasts and fibrosis in liver cancer. Annu Rev Pathol. 2017;12:153–186.
   PubMed Web of Science ®Google Scholar
• Attwa MH, El-Etreby SA. Guide for diagnosis and treatment of hepatocellular carcinoma. World J Hepatol. 2015;7:1632–1651.
   PubMed Web of Science ®Google Scholar
• Brito AF, Abrantes AM, Tralhão JG, et al. Targeting hepatocellular carcinoma: what did we discover so far? Oncol Rev. 2016;10:302–308.
   PubMed Web of Science ®Google Scholar
• Zhu L, Li T, Ma X, et al. A simple noninvasive index can predict hepatocellular carcinoma in patients with chronic hepatitis B. Sci Rep. 2017;7:8954–8963.
   PubMed Web of Science ®Google Scholar
• Reichl P, Mikulits W. Accuracy of novel diagnostic biomarkers for hepatocellular carcinoma: an update for clinicians. Oncol Rep. 2016;36:613–625.
   PubMed Web of Science ®Google Scholar
• Kee KM, Lu SN. Diagnostic efficacy of ultrasound in hepatocellular carcinoma diagnosis. Expert Rev Gastroenterol Hepatol. 2017;11:277–279.
   PubMed Web of Science ®Google Scholar
• Singal AG, Parikh ND, Rich NE, et al. Hepatocellular carcinoma surveillance and staging. In: Hoshida Y, editor. Hepatocellular carcinoma: translational precision medicine approaches. Cham (CH): Humana Press; 2019. p. 27–51.
   Google Scholar
• Chaiteerakij R, Addissie BD, Roberts LR. Update on biomarkers of hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2015;13:237–245.
   PubMed Web of Science ®Google Scholar
• Sahin T, Serin A, Emek E, et al. Effectiveness of noninvasive fibrosis markers for the prediction of hepatocellular carcinoma in chronic hepatitis B and chronic hepatitis B+D induced cirrhosis. Transplant Proc. 2019;51:2397–2402.
   PubMed Web of Science ®Google Scholar
• Patel J, Yopp A, Waljee AK, et al. Development and internal validation of a model for early detection of hepatocellular carcinoma in patients with cirrhosis. J Clin Gastroenterol. 2016;50:175–179.
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M. American association for the study of liver diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–1022.
   PubMed Web of Science ®Google Scholar
• Procopet B, Berzigotti A. Diagnosis of cirrhosis and portal hypertension: imaging, non-invasive markers of fibrosis and liver biopsy. Gastroenterol Rep (Oxf). 2017;5:79–89.
   PubMed Web of Science ®Google Scholar
• Attallah AM, Omran MM, Attallah AA, et al. HCC-ART score, a simple, highly sensitive and specific test for early diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Br J Cancer. 2013;109:1657–1665.
   PubMed Web of Science ®Google Scholar
• Attallah AM, Shiha GE, Omran MM, et al. A discriminant score based on four routine laboratory blood tests for accurate diagnosis of severe fibrosis and/or liver cirrhosis in Egyptian patients with chronic hepatitis C. Hepatol Res. 2006;34:163–169.
   PubMed Web of Science ®Google Scholar
• Botta F, Giannini E, Romagnoli P, et al. MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study. Gut. 2003;52:134–139.
   PubMed Web of Science ®Google Scholar
• Tseng PL, Wang JH, Hung CH, et al. Comparisons of noninvasive indices based on daily practice parameters for predicting liver cirrhosis in chronic hepatitis B and hepatitis C patients in hospital and community populations. Kaohsiung J Med Sci. 2013;29:385–395.
   PubMed Web of Science ®Google Scholar
• Ohta T, Sakaguchi K, Fujiwara A, et al. Simple surrogate index of the fibrosis stage in chronic hepatitis C patients using platelet count and serum albumin level. Acta Med Okayama. 2006;60:77–84.
   PubMed Web of Science ®Google Scholar
• Ahmad W, Ijaz B, Javed FT, et al. A comparison of four fibrosis indexes in chronic HCV: development of new fibrosis-cirrhosis index (FCI). BMC Gastroenterol. 2011;11:44–53.
   PubMed Web of Science ®Google Scholar
• Omran MM, Farid K, Emran TM, et al. Fibro-α score as a simple and useful noninvasive test for predicting significant liver fibrosis in chronic hepatitis C patients. Arab J Gastroenterol. 2011;12:74–79.
   PubMedGoogle Scholar
• Seto WK, Lee CF, Lai CL, et al. A new model using routinely available clinical parameters to predict significant liver fibrosis in chronic hepatitis B. PLoS One. 2011;6:e23077–83.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329–338.
   PubMed Web of Science ®Google Scholar
• CLIP. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatol. 1998;28:751–755.
   PubMed Web of Science ®Google Scholar
• Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Cancer. 1985;56:918–928.
   PubMed Web of Science ®Google Scholar
• Chan SL, Chan AW, Chan AK, et al. Systematic evaluation of circulating inflammatory markers for hepatocellular carcinoma. Liver Int. 2017;37:280–289.
   PubMed Web of Science ®Google Scholar
• Li C, Peng Y, Mao B, et al. Thioredoxin reductase: a novel, independent prognostic marker in patients with hepatocellular carcinoma. Oncotarget. 2015;6:17792–17804.
   PubMedGoogle Scholar
• Omran MM, Emran TM, Farid K, et al. An easy and useful noninvasive score based onα-1-acid glycoprotein and c- reactive protein for diagnosis of patients with hepatocellular carcinoma associated with hepatitis c virus infection. J Immunoassay Immunochem. 2016;37:273–288.
   PubMedGoogle Scholar
• Ma LN, Liu XY, Lu ZH, et al. Assessment of high-sensitivity C-reactive protein tests for the diagnosis of hepatocellular carcinoma in patients with hepatitis B-associated liver cirrhosis. Oncol Lett. 2017;13:3457–3464.
   PubMed Web of Science ®Google Scholar
• Adhoute X, Penaranda G, Raoul JL, et al. Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments. World J Hepatol. 2016;8:703–715.
   PubMed Web of Science ®Google Scholar
• Pang Q, Zhang JY, Xu XS, et al. Significance of platelet count and platelet-based models for hepatocellular carcinoma recurrence. World J Gastroenterol. 2015;21:5607–5621.
   PubMed Web of Science ®Google Scholar
• Abdelgawad IA. Clinical utility of simple non-invasive liver fibrosis indices for predicting hepatocellular carcinoma (HCC) among Egyptian patients. J Clin Pathol. 2015;68:154–160.
   PubMed Web of Science ®Google Scholar
• Mobarak L, Omran D, Nabeel MM, et al. Fibro markers for prediction of hepatocellular carcinoma in Egyptian patients with chronic liver disease. J MedVirol. 2017;89:1062–1068.
   Google Scholar
• Attallah AM, Omran MM, Farid K, et al. Development of a novel score for liver fibrosis staging and comparison with eight simple laboratory scores in large numbers of HCV-monoinfected patients. Clin Chim Acta. 2012;413:1725–1730.
   PubMed Web of Science ®Google Scholar
• Attallah AM, El-Far M, Omran MM, et al. Noninvasive diagnosis of liver fibrosis and cirrhosis in chronic hepatitis C patients. J Clin Lab Anal. 2013;27:121–129.
   PubMed Web of Science ®Google Scholar
• Attallah AM, Omran MM, Attallah AA, et al. Simplified HCC-ART score for highly sensitive detection of small-sized and early stage hepatocellular carcinoma in the widely used Okuda, CLIP, and BCLC staging systems. Int J Clin Oncol. 2017;22:332–339.
   PubMed Web of Science ®Google Scholar